Oxemia 25 Tablet contains Desidustat 25mg, a potent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated for the treatment of anemia associated with chronic kidney disease (CKD). By stabilizing hypoxia-inducible factors, Desidustat promotes endogenous erythropoietin production, enhancing erythropoiesis and improving hemoglobin levels. Oxemia 25 is administered orally and is suitable for both dialysis-dependent and non-dialysis-dependent CKD patients. Clinical studies have demonstrated its efficacy in reducing the need for exogenous erythropoiesis-stimulating agents (ESAs) and minimizing iron supplementation requirements. The drug is generally well-tolerated; however, monitoring of hemoglobin levels, blood pressure, and iron parameters is recommended during therapy to avoid adverse effects such as hypertension, thromboembolic events, or iron overload. Oxemia 25 should be used under medical supervision, with dosage adjustments based on patient response and laboratory values. It is contraindicated in patients with known hypersensitivity to Desidustat or any excipients. Caution is advised in patients with a history of cardiovascular disease or malignancy. Overall, Oxemia 25 Tablet offers a novel, effective oral treatment option for anemia in CKD, improving patient quality of life and reducing dependence on injectable therapies.